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Background: Catechol-O-methyltransferase (COMT) metabolizes dopamine. The COMT Val158Met polymorphism influences its activity,
nd multiple neural correlates of this genotype on dopaminergic phenotypes, especially working memory, have been reported. COMT
ctivity can also be regulated pharmacologically by COMT inhibitors. The inverted-U relationship between cortical dopamine signaling and
orking memory predicts that the effects of COMT inhibition will differ according to COMT genotype.
ethods: Thirty-four COMT Met158Met (Met-COMT) and 33 COMT Val158Val (Val-COMT) men were given a single 200-mg dose of the
brain-penetrant COMT inhibitor tolcaponeor placebo in a randomized, double-blind, between-subjects design. They completed theN-back
task of working memory and a gambling task.
Results: In the placebo group, Met-COMT subjects outperformed Val-COMT subjects on the 2- back, and they were more risk averse.
Tolcapone had opposite effects in the two genotype groups: it worsened N-back performance in Met-COMT subjects but enhanced it in
Val-COMT subjects. TolcaponemadeMet-COMT subjects less risk averse but Val-COMT subjects more so. In both tasks, tolcapone reversed
the baseline genotype differences.
Conclusions: Depending on genotype, COMT inhibition can enhance or impair working memory and increase or decrease risky decision
making. To our knowledge, the data are the clearest demonstration to date that the direction of effect of a drug can be influenced by a
polymorphism in its target gene. The results support the inverted-Umodel of dopamine function. Thefindings are of translational relevance,
because COMT inhibitors are used in the adjunctive treatment of Parkinson’s disease and are under evaluation in schizophrenia and other
disorders.
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A n inverted-U relationship has been proposed between do-pamine and prefrontal cortex function in which too little ortoomuch dopamine signaling impairs workingmemory (1–
). Both genetic and pharmacologic factors can affect position on
he curve. The enzyme catechol-O-methyltransferase (COMT) me-
abolizes dopamine and is one such influence (5–9). COMT activity
s genetically influenced, with the greatest variance explained by a
ommon polymorphism, Val158Met, which is associated with a ap-
roximately 35% enzyme activity difference between homozy-
otes (Val-COMTMet-COMT) in humanbrain (10); this is reflected
in a genotypedifference in cortical D1dopamine receptor availabil-
ity, a proxy measure of cortical dopamine (11). In turn, as shown
initially by Egan et al. (12) and confirmed inmany other studies (13),
there are robust Val158Met genotype effects on cortical activation
uring tasks of workingmemory and executive function. Val158Met
genotype differences in working memory performance have also
been reported (12,14), although less consistently (15). COMT activ-
ity can also be regulated pharmacologically by COMT inhibitors,
with corresponding cognitive, behavioral, and neurochemical ef-
fects, in rodents (16,17) and humans (18–21).
The inverted-U model predicts that COMT inhibition should
have differential effects on working memory depending on
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doi:10.1016/j.biopsych.2011.12.023al158Met genotype. That is, the effect of being moved rightward
n the curve (because COMT inhibition increases prefrontal dopa-
ine) (16) will be affected by the starting position: Val-COMT sub-
ects, with their higher COMT activity, sit to the left of Met-COMT
ubjects. COMT inhibition will thus tend to move Val-COMT sub-
ects closer to the optimumand enhance performance, whilstmov-
ng Met-COMT subjects beyond the peak and impairing perfor-
ance. To date, tests of this focused pharmacogenetic hypothesis
re intriguing but inconclusive (19,20), although COMT Val158Met
enotype has been shown to modulate responses to other dopa-
inergic drugs including amphetamine (22), antipsychotics (23),
nd methylphenidate (24).
Here we recruited Val-COMT and Met-COMT homozygote men,
ave them the brain-penetrant COMT inhibitor tolcapone (25,26),
r placebo, and measured their performance on the N-back task of
orking memory. Because the possibility that an inverted-U rela-
ionship may extend to other dopamine-modulated phenotypes
emains less well explored, we also tested the subjects’ perfor-
ance on a gambling task.
ethods andMaterials
articipants
The study was approved by the Oxfordshire National Health
ervice Research Ethics Committee B (09/H0605/69). Healthy men
ged 18 to 50 years old were recruited by advertisement. They had
o history of psychiatric or neurologic disorder, and none were
aking psychotropic medication. Alcohol and smoking use was re-
orded, and all subjects denied use of illicit substances. Subjects
ith alcohol intake greater than 30 units/week or a history of liver
isease were excluded because of the hepatotoxicity risk with tol-
apone. Participants were genotyped for the Val158Met polymor-
hism. We selected only homozygotes (Met-COMT and Val-COMT),
ecause these represent low and high COMT activity, respectively,
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S.M. Farrell et al. BIOL PSYCHIATRY 2012;71:538–544 539with heterozygotes being intermediate (10) and therefore less in-
formative in the present context. The subjects were unrelated to
eachother. Sixty-seven subjectsperformed thegambling task, 60of
whomalso carriedout theN-back (Table 1). Subjects completed the
National Adult Reading Test and depression and anxiety invento-
ries. On the day of testing, they completed visual analogue scale
(VAS) ratings of alertness, drowsiness, happiness, sadness, anxiety,
and nausea; these were completed on arrival and again approxi-
mately 90 min and then approximately 120 min later.
Within each genotype group, subjects were randomly assigned
to tolcapone (200 mg by mouth) or placebo. A between-subjects
designwas chosen to avoid order or practice effects. The studywas
double-blind, with matching capsules prepared by a pharmacy
registered under U.K. Good Manufacturing Practice regulations.
Tolcapone has an elimination half-life of 2.0  .8 hours, and the
dosegivenproduces 70% to80%peripheral bloodCOMT inhibition
between 1 and 4 hours (25,27). Testing began 90min after swallow-
ing the capsule and lasted90 min. Testing was carried out while
subjects were in a magnetoencephalography (MEG) scanner; MEG
results will be reported separately. After testing, subjects were
asked to guess whether they had received tolcapone or placebo.
Genotyping
DNA was extracted from buccal swabs and genotyped for
Val158Met using the appropriate Taqman SNP Genotyping Assay
Applied Biosystems, Carlsbad, California), in duplicate. A subset of
enotypes were confirmed using a restriction fragment length
olymorphism assay (28). Genotype calls agreed in all cases. No
ther polymorphisms were measured, reflecting the hypothesis-
riven nature of the study.
-Back Task of WorkingMemory
In theN-back task as instantiated here, a number between 1 and
is shown at random on a screen. For the 0-back, subjects respond
o the number currently showing on the screen by pressing the
ppropriate button; for the 1-back, subjects respond to the previ-
us number on the screen, and so on for 2- and 3-back conditions.
ach number is shown for 160 msec, with an interval of 1640 msec
etween numbers (and 3000 msec between blocks). The task im-
oses a parametric load on working memory, and the version we
sed is relatively demanding (29). The primary performance mea-
ure is accuracy (correct responses); we also measured reaction
Table 1. Demographics of Subjects
Met-COMT,
Placebo
Val-CO
Place
Numbera 18 16
Ethnicityb 17C, 1I 12C, 2I, 1
Age (Years) 22.6 (3.2) 24.0
NART 118 (4) 117
Alcohol (Units/Week) 10 (7) 8 (
Cigarettes/Day 0 (0) .4 (1
BDI 3.9 (5.3) 3.5 (
STAI 32 (8) 39
Values are mean (SD).
ANOVA, analysis of variance; BDI, Beck Depression
genotype; NART, National Adult Reading Test; STAI, Spie
aSeven subjects completed the gambling task but n
follows:n15 (Met-COMTplacebo), 15 (Val-COMTplace
The demographics of the 60 who completed the N-bac
sample.
bC, Caucasian; Ch, Chinese; I, Indian; A, African Caribbime (RT). Tambling Task
The task involves monetary decision making based on a choice
etween gambling a high or a low amount (30). The task has been
sed extensively for studies of decision making and risky choice;
lectroencephalographic responses during the task are sensitive to
OMTVal158Met (31). Subjects are given £10 (approximately $15) to
lay with. Two gray boxes are shown on a screen, with “5” or “25”
hownwithin each box. The subject selects one box, and the choice
eans they are gambling either 5 or 25 pence. Once the choice is
ade, the boxes change color, either to green (indicating a win) or
o red (indicating a loss). Both boxesmay go red, both green, or one
f each. Thus, a subject can win when they could have lost, lose
hen they could have won, win a small amount when they could
ave won a large amount, and so on. Intermittently, the screen
hows howmuchmoney is currently banked. The primarymeasure
f interest is simply the percentage of bets that were “5” not “25.”
e also calculated this for bets that followed two successive wins,
r two successive losses, because Val158Met genotype has been
eported to affect sensitivity to losses versus rewards (32,33).
tatistical Analysis
Analyses were carried out in SPSS for Windows (version 17.0;
PSS Statistics Inc., Chicago, Illinois). For the N-back, we first con-
ucted a repeated-measures analysis of variance (ANOVA), with
ifficulty (back condition) as the within-subjects factor and drug
ndgenotype as thebetween-subjects factors. Eachback condition
as then examined with a two-way ANOVA with drug and geno-
ypeasbetween-subjects factors. Post hoc comparisonsweremade
sing t tests (two-tailed). For the gambling task, we used two-way
NOVA with drug and genotype as between-subjects factors. Cor-
elations between variables were explored using Pearson’s coeffi-
ient. Significance was set at  .05.
esults
The drug blindwasmaintained, with 59 of the 67 subjects think-
ng that they had received placebo, including 30 of the 33 who had
n fact had tolcapone.
-Back Performance
There were no main effects of drug or genotype on N-back
ccuracy, nor interactions betweendrugor genotype anddifficulty.
Met-COMT,
Placebo
Met-COMT,
Placebo
ANOVA,
p
16 17
A 16C 14C, 2I, 1Ch
24.4 (9.0) 23.9 (3.9) .80
115 (5) 116 (6) .23
7 (5) 8 (8) .59
.4 (1.5) .2 (.7) .60
3.7 (3.7) 3.1 (2.9) .89
33 (10) 37 (8) .09
ntory; COMT, catechol-O-methyltransferase Val158Met
er Trait Anxiety Inventory.
e N-back. Final sample size for the N-back task was as
6 (Met-COMT tolcapone), and14 (Val-COMT tolcapone).
e virtually identical to those given here for the wholeMT,
bo
Ch, 1
(5.1)
(5)
5)
.3)
3.3)
(7)
Inve
lberg
ot th
bo), 1
k werhere was a genotype drug difficulty interaction from 0-back
www.sobp.org/journal
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540 BIOL PSYCHIATRY 2012;71:538–544 S.M. Farrell et al.to 3-back [F (2.33,130.3)  3.9, p  .018], and a genotype  drug
nteraction for all conditions (Figure 1 and Figure S1A in Supple-
ent 1).
Themost striking resultswere seen for the2-back (Figure1C).On
lacebo, Met-COMT subjects out-performed Val-COMT subjects
p .006), but in the tolcapone group, this difference was reversed
such that Val-COMT subjects outperformed Met-COMT subjects
(p  .022); tolcapone significantly impaired performance in Met-
OMT subjects (p  .019) and improved it in Val-COMT subjects
p  .007). For the 0- and 1-back, on placebo, Met-COMT and Val-
OMT subjects performed similarly, but accuracy was impaired in
et-COMT subjects given tolcapone compared with those given
lacebo (0-back, p  .002; 1-back, p  .043; Figure 1A and 1B).
onsequently, in subjects given tolcapone, Val-COMT subjects per-
ormed better than Met-COMT subjects (0-back, p  .017; 1-back,
p .013). Results for the 3-back were similar to the 2-back but less
significant (Figure 1D). Thegenotypedrug interaction accounted
for 19% of overall N-back performance (partial h2), and for 13.5%,
9%, 15.5%, and 9% of the variance in 0, 1, 2, and 3-back perfor-
mance, respectively (adjusted R2).
Because a significant drug genotype interaction was seen for
he 0-back condition, in which working memory is not explicitly t
www.sobp.org/journalequired, we performed a supplementary analysis to investigate
hether COMT affects workingmemorywhen 0-back performance
s controlled for. For each subject, 1-, 2-, and 3-back performance
as expressed as a percentage of 0-back performance and entered
nto a repeated-measures ANOVA with three levels of difficulty (1-,
-, and3-back). This analysis showedadruggenotype interaction
F (1,60)  9.2; p  .004], with Met-COMT subjects outperforming
al-COMT subjects in the placebo groups (p .024) and Val-COMT
ubjects tending to outperform Met-COMT subjects in the tolca-
one groups (p  .053). Thus, an interaction between drug and
enotype on working memory remained when 0-back perfor-
ance was taken into account.
Reaction times for each N-back condition are shown in Table 2
nd Figure S1B in the Supplement. We found a trend-level RT 
enotype interaction [F (1.86,98.7)  2.79, p  .070], with Met-
OMT subjects reacting faster than Val-COMT subjects (p  .049).
olcapone decreased RT in Val-COMT (p  .046) but not in Met-
OMT (p  .61) subjects. On placebo, Met-COMT subjects reacted
aster than Val-COMT subjects on the 2-back (p .046) and 3-back
p .039); no genotype differences in RT were seen for subjects on
Figure 1. Interactive behavioral effects of catechol-O-
methyltransferase (COMT) genotype and COMT inhibi-
tion. (A) 0-back: main effect of drug [F(1,56)  4.14, p 
.047] and genotype  drug interaction [F(1,56)  6.75,
p  .012]. Met-COMT subjects given tolcapone perform
worse than those given placebo. (B) 1-back: genotype
drug interaction [F(1,56)  9.26, p  .006]. Tolcapone
impairs performance in Met-COMT subjects and, as a
trend, improves it in Val-COMT subjects, compared with
their respective placebo groups. (C) 2-back: genotype
drug interaction [F(1,56)  13.62, p  .001]. Met-COMT
subjects perform better than Val-COMT subjects on pla-
cebo. Tolcapone reverses this difference, impairing Met-
COMT subjects and enhancing Val-COMT subjects, com-
pared with their respective placebo groups. (D) 3-back.
Genotype  drug interaction [F(1,56)  8.03, p  .006].
Val-COMT subjects given tolcapone perform better than
thosegivenplacebo. (E)Gambling task, showingpercent-
age of times when 5 not 25 was gambled. Genotype 
drug interaction [F(1,61)  7.91, p  .007]. On placebo,
Met-COMT subjects are more likely than Val-COMT sub-
jects to make a small rather than a large bet. Tolcapone
reverses this difference,makingVal-COMT subjects signif-
icantly more risk averse, compared with those given pla-
cebo. (F)Happiness visual analogue scale (VAS) ratings for
tolcapone-treated subjects. Data are adjusted means
with standard errors. Time 1: immediately before drug
administration. Time 2: T1 90min. 3: T1 210minutes.
*p .026. SeeTableS2 inSupplement1 forhappinessVAS
ratings in the placebo groups.olcapone.
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There was a genotype  drug interaction for the size of bet
placed [F (1,61)  7.91, p  .007]. In the subjects given placebo,
Met-COMT subjects mademore small bets than Val-COMT subjects
(p .05); this difference was reversed in subjects given tolcapone
(p  .025; Figure 1E), with tolcapone-treated Val-COMT subjects
beingmore risk averse than tolcapone-treatedMet-COMT subjects
(p  .008). Drug and genotype together explained 8.5% of the
variance. As noted, Val158Met genotype may affect sensitivity to
losses versus rewards (32,33), but our findings were unaffected by
the outcomes of prior trials. That is, the main effects and interac-
tions shown in Figure 1Ewere also seen for trials following twowins
or two losses or other combinations of prior outcomes (Table 2 and
datanot shown).We foundnomaineffects of drugorgenotype, nor
interactions, on gambling task RT (Table 2; all Fs1.5, p .3).
Other Measures and Correlations
On the VAS ratings, Met-COMT subjects rated themselves hap-
pier than Val-COMT subjects overall [7.2 .3 vs. 6.3 .3; F (1,61)
5.58, p .021], including at baseline [7.1 .3 vs. 6.0 .3; p .013].
Happiness also showed a drug  genotype  time interaction
[F (1.70,103.9)3.3,p .037]due toan increase in ratingswith time
in the Val-COMT tolcapone group (p .015, comparing time points
1 and 3) that was absent in other groups (Figure 1F). None of the
other VAS ratings were affected by genotype or drug (Table S1 in
Supplement 1), nor did the groups differ in their depression and
anxiety inventory ratings (Table 1).
Because we found drug  genotype interactions on N-back
performance, risky decision making, and the happiness VAS rating,
we investigated whether these variables correlated with each
other. However, there were no significant correlations (	.13 R
.23; all ps .05; Table S2 in Supplement 1). Neither did inclusion of
happiness VAS score as a covariate affect the N-back or gambling
task results (data not shown).
Discussion
Our study has two main findings. First, on placebo, Met-COMT
subjects outperformed Val-COMT on the 2-back task of working
memory and were more risk averse. Second, and more notably,
genotype interacted with COMT inhibition by tolcapone to affect
Table 2. Reaction Times and Additional Gambling Task
Met-COMT,
Placebo
N-Back Taska (msec)
0-Back RT 504 (99)
1-Back RT 540 (199)
2-Back RT 653 (237)
3-Back RT 706 (290)
Gambling Taskb
RT (msec) 730 (333)
Choose 5 after 2 gainsc (%) 57 (21)
Choose 5 after 2 lossesd (%) 45 (22)
Values are mean (SD).
COMT, catechol-O-methyltransferase Val158Met geno
aRT not available for three subjects. For statistics, see
bRT not available for 10 subjects.
cGenotype drug interaction [F(1,61) 5.96, p .0
.036.
dGenotype drug interaction [F(1,61) 6.65, p .0
.023. For Val-COMT, tolcapone placebo, p .043.both these indices. Comparedwith those given placebo, tolcapone tmprovedworkingmemory in Val-COMT subjects but impaired it in
et-COMT subjects; it made Met-COMT subjects less risk averse
nd Val-COMT subjects more so. These interactions were qualita-
ive and robust, and the drug effect was sufficient to reverse base-
inegenotypedifferences. Theeffectswerealsoofnotable size,with
al158Met genotype and tolcapone together accounting for 19%of
he variance in N-back performance. This is substantial, especially
iven that we did not include the contribution of other genetic
21,34,35) and epigenetic (36) sources of COMT variation nor poly-
orphisms in interacting dopaminergic genes (37–39). These re-
ults are significant with regard to the range of phenotypes with
hich COMT is associated, the inverted-U model of cortical dopa-
ine, and from a pharmacogenetic perspective. Our findings sup-
ort the hypothesis that COMT genotype influences not just the
agnitude but the direction of cognitive and behavioral responses
o COMT inhibition.
Our findings that, on placebo, Met-COMT subjects performed
etter than Val-COMT subjects at the 2-back replicates the result of
ne large study (15,40) but many other studies (e.g., Blanchard et
l.) (41) and a meta-analysis (14) have been negative. The differ-
nces likely reflect the fact that the nature of the N-back task differs
etween different versions; we used one with high updating and
nterference management demands thought to be more depen-
ent on COMT (29,42). Our task was also relatively difficult, as
hown by the performance data, perhaps because subjects were
ew to the task and given only brief instruction, and they com-
leted it in theMEG scanner. Limiting our study to youngmenwith
n above-average and restricted range of verbal IQ (National Adult
eading Test scores ranged from108 to 125)may also have contrib-
ted, given gender- (43,44), age- (45,46), and possibly IQ-related
14) variation in COMT function.
Two prior studies have investigated interactive effects of tolca-
oneandVal158Metonworkingmemoryandexecutive functioning
nd gave more equivocal results than we report here. Apud and
olleagues (19) used repeated tolcapone administration (200 mg
hree times a day for a week) in a within-subjects crossover design.
hey did not identify any main effects or interactions on N-back
ccuracy but did find an interaction on intradimensional set shift-
ng, such that tolcapone improvedVal-COMT subjects but impaired
et-COMT subjects. Giakoumaki et al. (20) used a single dose of
Val-COMT,
Placebo
Met-COMT,
Tolcapone
Val-COMT,
Tolcapone
494 (68) 531 (104) 488 (65)
627 (200) 608 (200) 497 (172)
844 (256) 693 (233) 687 (282)
916 (269) 690 (255) 707 (245)
715 (331) 884 (557) 667 (187)
50 (17) 47 (19) 63 (18)
34 (15) 38 (16) 50 (18)
; RT, reaction time.
or subjects on tolcapone, Val-COMTMet-COMT, p
or subjects on tolcapone, Val-COMTMet-COMT, pData
type
text.
18]. Folcapone (200 mg) in a within-subjects crossover design. They
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542 BIOL PSYCHIATRY 2012;71:538–544 S.M. Farrell et al.found no drug genotype interaction for N-back accuracy but did
for N-back RT, which was improved by tolcapone in Val- but not
Met-COMT subjects. They also found a trend-level effect on letter-
number sequencing, another test of working memory, with tolca-
pone again selectively improving Val-COMT subjects. Overall,
therefore, all studies agree that tolcapone and genotype have in-
teractive effects on executive functioning, with tolcapone enhanc-
ing Val-COMT subjects but either not improving or impairing Met-
COMT subjects. The demographic and methodological factors
mentioned earlier are probably relevant in explainingwhywe iden-
tified more robust drug  genotype interactions, specifically on
N-back performance, thandid theprior studies;moreover, our sam-
ple of homozygotes (n  60–67) is considerably larger than the
number included in the earlier studies (n 22–23).
Our other findings highlight that COMT has roles in a range of
phenotypes beyond executive function andworkingmemory (6,7).
First, involvement of COMT in dopaminergic contributions to deci-
sion making and reward has hitherto been demonstrated in rela-
tively complex paradigms (47–50), but our gambling task data
show that even the simple trait of risky decision making is affected
by COMT: high COMT activity is associated with making a higher
proportion of large gambles (risky choices) compared with low
COMT activity. This findingmay relate to the recent demonstration
in rodents that enhanced dopamine signaling via D2 receptors
promotes risk aversion (51). Second, the effect of tolcapone on
0-back performance suggests an influence of COMT on attention,
consistent with prior evidence for COMTmodulation of attentional
processes (52,53). Third, we found some evidence for an effect on
mood state (the happiness VAS), which may relate to evidence
linking COMTVal158Metwith affective processing (12,54). However,
one of our other trait or state ratings nor the earlier tolcapone
tudies (19,20) found any effects of tolcapone on affect or well-
eing, and so we view this result with caution. Nevertheless, the
esults in total emphasize the pleiotropic nature of COMT and the
eed to consider affective and attentional contributions to itsmod-
lation of working memory or other higher level cognitive pro-
esses.
The genotype  drug interactions support the inverted-U
odel of dopamine function, and for a genetic and pharmacologic
ontribution fromCOMT to this relationship, based on the rationale
utlined earlier and illustrated in Figure 2. The gambling task data
ighlight that an inverted-U may well apply not only to working
emory but to other dopamine-modulated behaviors (2,4). It is
ossible that the various findings could be explained in terms of
ifferent manifestations of a single inverted-U, but the absence of
ny correlations between COMT’s effects on working memory and
isky decision making suggests that there is at least a partial sepa-
ation of the underlying neural circuits and mechanisms. However,
n humans, it is difficult to test critically the inverted-U concept or to
istinguishbetween variants of it. Instead, formal testing canbetter
e conducted in pharmacologic studies of humanized transgenic
ice that mimic the human Val158Met polymorphism (55). Such
tudies will also provide the opportunity to investigate the cellular
nd synaptic processes involved. For example, the balance be-
ween D1 and D2 receptor signaling, high and low D2 receptor
ffinity states, and other putative mechanisms (8).
In summary, our results provide a striking and “lawful” example
f a genotype  drug interaction. That is, the functionality of the
ene is known (viz., it metabolizes dopamine), as is that of the Val158Met
olymorphism (viz., it influences enzyme activity); the drug effec-
ively and selectively targets the protein encoded by the gene; and
he predicted effects are grounded in a well-established systems-
evel model (viz., the inverted-U of cortical dopamine signaling).
www.sobp.org/journaluch a pharmacogenetically favorable set of circumstances is rare
nd may explain why, to our knowledge, COMT provides the clear-
st demonstration to date of a qualitative pharmacogenetic effect
n which not just themagnitude but the direction of the behavioral
ffect of a drug is determined by variation in sequence of its target
ene. Equally, the fact that prior studies did not find such clear cut
esults attests to the many other factors that can obscure this rela-
ionship.
Finally, thefindingshave translational implications. COMT inhib-
tors are licensed as adjunctive therapy for Parkinson’s disease and
re under investigation in schizophrenia and other neuropsychiat-
ic conditions (56,57). Extending earlier findings (19,20), our results
how that COMT Val158Met genotype can affect the cognitive, be-
avioral, and perhaps affective responses to these drugs; genotype
ay also influence their toxicity (58). Thus, genotype will be worth
easuring in the ongoing trials and including in the design of
uture ones. However, the results will likely vary between COMT
nhibitors according to their central bioavailability and pharmaco-
inetics, as well as between diseases depending on the nature and
everity of dopaminergic involvement in their pathophysiology
4,59–62).
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